- $46.16m
- -$41.88m
- $0.10m
Annual income statement for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
R2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.88 | 0 | 0.225 | 0.4 | 0.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 31.6 | 29.3 | 16.9 | 19 | 35.2 |
| Operating Profit | -29.7 | -29.3 | -16.6 | -18.6 | -35.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.5 | -29.3 | -15.4 | -18.4 | -33 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -29.5 | -29.3 | -15.4 | -18.4 | -33 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -50.3 | -65 | -24.9 | -18.4 | -33 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -50.4 | -65 | -24.9 | -18.4 | -33 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -63.8 | -47 | -4.29 | -1.75 | -0.269 |